文献速递儿童呼吸儿童感染

超越哮吼:基于表型视角的儿童副流感病毒类型解析

Beyond Croup: A Phenotype-Based Perspective on Parainfluenza Virus Types in Children.
PubMed 文献 · Pediatrics · 2026-11-13

4种型别在分类学、嗜性、临床综合征和严重程度上差异显著,PIV-1是哮吼最常见病因并在幼儿中引起隔年流行,PIV-2较少见但可致重症,PIV-3在年幼婴儿中占优势且临床类似RSV感染,PIV-4常不引起哮吼但与下呼吸道疾病、低氧血症及偶发神经系统并发症相关。多重分子诊断可快速分型,目前无疫苗或抗病毒药物获批。

要点

  • PIV-1是哮吼最常见病因,在幼儿中引起隔年流行。
  • PIV-3在年幼婴儿中占优势,引起临床类似RSV感染的细支气管炎和肺炎。
  • PIV-4常不引起哮吼,但与下呼吸道疾病、低氧血症及偶发神经系统并发症相关。

核心结论

  • 认识每种PIV型别独特的流行病学、临床特征和免疫反应,对儿科诊疗及开发针对性预防和治疗策略至关重要。

研究设计与样本

  • 本文为综述,汇总PIV各型别的分类学、嗜性、临床综合征、严重程度、季节模式及诊断治疗进展。

主要发现

  • PIV-1是哮吼最常见病因,在幼儿中引起隔年流行;PIV-2较少见但可致严重疾病,尤其在有基础疾病的儿童中。
  • PIV-3在年幼婴儿中占优势,引起临床类似RSV感染的细支气管炎和肺炎,反映其出生后早期易感性,可能与更早、更频繁的病毒暴露有关。
  • PIV-4因培养限制历史上认识不足,通常不引起哮吼,但与下呼吸道疾病、低氧血症及偶发神经系统并发症相关。
  • PIV感染在婴儿、免疫受损儿童和低资源环境儿童中最为严重;季节模式因型别和地理而异。

关键数值与推荐

  • 多重分子诊断进步使快速型别特异性检测成为可能,改善临床解读和管理。
  • 尚无疫苗或抗病毒药物获批。
  • 新兴治疗包括获美国食品药品监督管理局突破性疗法认定的唾液酸酶基抗病毒药物、能交叉中和PIV-1、PIV-3、RSV和人偏肺病毒的单克隆抗体,以及在儿童中显示早期免疫原性的信使RNA疫苗。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Human parainfluenza viruses (PIVs) caused an estimated 18.8 million acute lower respiratory infection episodes, 725 000 hospitalizations, and 34 400 deaths among children under 5 in 2018, ranking second only to respiratory syncytial virus (RSV). Despite this burden, clinical attention has historically focused on croup, leading to the common perception that parainfluenza is a single disease entity. However, the 4 types differ substantially in taxonomy, tropism, clinical syndrome, and severity. PIV-1, the most common cause of croup, drives biennial epidemics in toddlers, whereas PIV-2 is less frequent but can cause severe disease, particularly in children with underlying conditions. PIV-3 predominates in young infants, causing bronchiolitis and pneumonia clinically like RSV infection, reflecting its early postnatal susceptibility, which may relate to earlier and more frequent viral exposure. PIV-4, historically underrecognized due to culture limitations, usually does not cause croup but is linked to lower respiratory tract disease, hypoxemia, and occasional neurologic complications. PIV infections are most severe in infants, immunocompromised children, and those in low-resource settings. Seasonal patterns vary by type and geography. Advances in multiplex molecular diagnostics now allow rapid type-specific detection, improving clinical interpretation and management. No vaccine or antiviral is licensed. Emerging therapeutics include sialidase-based antivirals with Food and Drug Administration Breakthrough designation; monoclonal antibodies capable of cross-neutralizing PIV-1, PIV-3, RSV, and human metapneumovirus; and messenger RNA vaccines showing early immunogenicity in children. Recognizing the distinct epidemiology, clinical features, and immune responses of each type is critical for informed pediatric care and the development of targeted preventive and therapeutic strategies.

来源:Pediatrics,查看原文。版权归原作者所有。

引用

  1. Jaramillo-Cerezo A, Parra-Buitrago A, Ulloa-Gutierrez R, et al. Beyond Croup: A Phenotype-Based Perspective on Parainfluenza Virus Types in Children. Pediatrics. 2026. PMID: 43020122. doi:10.1542/peds.2026-078012

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。